Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRDN-001 MAD Safety, Tolerability and Efficacy Study in Healthy Volunteers and Thyroid Eye Disease (THRIVE pivotal, Phase 3)
2024-512244-36-00Phase 3Completed
- Sponsor
- Viridian Therapeutics
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing VRDN-001 with Placebo (sodium chloride) (2 arms). Primary endpoints: Safety: Adverse Events and Serious Adverse Events, Proptosis Responder Rate in study eye at Week 15 (USA, Canada, China; THRIVE pivotal) and 1 more. Started Oct 2024; status: completed.
02
Drugs
veligrotug
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2024-512244-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512244-36-00.